APLS Q2 2023 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$3B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$95M+481.8% YoY

Gross Profit

$87M91.2% margin

Operating Income

-$120M-126.8% margin

Net Income

-$122M-128.5% margin

EPS (Diluted)

$-1.02

QoQ Revenue Growth

+111.8%

Cash Flow

Operating Cash Flow

-$150M

Free Cash Flow

-$151M

Stock-Based Comp.

$29M

Balance Sheet

Total Assets

$916M

Total Liabilities

$570M

Stockholders' Equity

$345M

Cash & Equivalents

$616M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$95M	$16M	+481.8%
Gross Profit	$87M	$16M	+433.2%
Operating Income	-$120M	-$149M	+19.0%
Net Income	-$122M	-$156M	+21.8%

Revenue Segments

Product

$90M94%

Licensing And Other Revenue

$5M6%